Troubled IRB closes shop

A company that serves as an independent review board for clinical trials and was caught approving a fake medical device study will close, the Wall Street Journal linkurl:reports.;http://online.wsj.com/article/SB124042341694744375.html The company, Colorado-based linkurl:Coast IRB,;http://www.coastirb.com/ was exposed in a government sting operation last month. Based on the undercover investigation's findings, the US Food and Drug Administration (FDA) sent Coast a formal reprimand on April 14 f

Written byAlla Katsnelson
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
A company that serves as an independent review board for clinical trials and was caught approving a fake medical device study will close, the Wall Street Journal linkurl:reports.;http://online.wsj.com/article/SB124042341694744375.html The company, Colorado-based linkurl:Coast IRB,;http://www.coastirb.com/ was exposed in a government sting operation last month. Based on the undercover investigation's findings, the US Food and Drug Administration (FDA) sent Coast a formal reprimand on April 14 for violating rules protecting clinical trial subjects. The FDA's action resulted in Coast freezing some of its key operations and promising to devise a plan to correct its shoddy practices by the end of the month. In a linkurl:letter;http://s.wsj.net/public/resources/documents/WSJ_Letter-Coast-employees-Board-Members_041709.pdf sent to employees and board members last week and posted today (April 22) by the WSJ, the company wrote that as a result of the FDA's letter, "several key customers have already pulled their studies from Coast IRB. Thus, it was determined that Coast IRB, LLC should immediately terminate all existing projects and transfer the studies to another IRB."
**__Related stories:__*** linkurl:FDA censures lax IRB;http://www.the-scientist.com/blog/display/55616/
[ 14th April 2009]*linkurl:Trial safety lacking, says GAO;http://www.the-scientist.com/blog/display/55546/
[26th March 2009]*linkurl:Subject death halts clinical trial;http://www.the-scientist.com/blog/display/54825/
[8th July 2008]*linkurl:Paying for patients;http://www.the-scientist.com/article/display/54196/
[February 2008]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies